Branched-chain ketoacid dehydrogenase kinase (BDK)

Class

BDK inhibitor/degrader (BCAA metabolism modulator)

Branched-chain ketoacid dehydrogenase kinase (BDK, also called BCKDK) is a mitochondrial enzyme that acts as a molecular brake on the breakdown of the branched-chain amino acids (BCAAs) leucine, isoleucine, and valine. It does this by adding a phosphate group to, and thereby inactivating, the enzyme complex that performs the first committed step of BCAA breakdown. When BDK activity is high, BCAAs and their intermediate breakdown products (branched-chain ketoacids) accumulate in the blood and tissues. Elevated levels of these metabolites have been associated with cardiac dysfunction, insulin resistance, and broader disturbances in cellular energy metabolism. The pharmacological rationale for inhibiting BDK is to release this brake, allowing the downstream enzyme complex to remain active and drive continued clearance of BCAAs and their metabolites. This approach is being explored primarily in cardiometabolic disease, including heart failure and conditions marked by impaired glucose and lipid handling, where lowering circulating BCAA burden may support better organ function. Because BCAA metabolism is a tightly regulated, whole-body process spanning muscle, liver, and heart, modulating this single kinase has systemic rather than localized effects, distinguishing it from more organ-restricted drug mechanisms.